Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-icap No.1 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head office: Sakyo-ku, Kyoto; Representative Director: Kimi Kusumi) as unlimited liability partner, has made an additional investment in Tregem Biopharma Inc. (Head office: Sakyo-ku, Kyoto; Representative Director: Honoka Kihaya), a venture company utilizing research results from Kyoto University.

Outline of this investment
TREGEM is a Kyoto University venture to develop the world's first antibody drug for tooth regeneration, established based on the research results of Dr. Katsu Takahashi, Chief Director of Dental and Oral Surgery at Kitano Hospital, Tazuke Kofukai Medical Research Institute (Associate Professor at Kyoto University Graduate School of Medicine until December 2020). It has been shown that USAG-1 protein (an antagonist of BMP (bone morphogenetic protein)/Wnt) is involved in the process of tooth development and that a neutralizing antibody that inhibits USAG-1 restores missing teeth together with alveolar bone in an animal model of edentulism. Tregem aims to commercialize USAG-1 neutralizing antibody and has succeeded in humanization of this antibody.

With this financing, Tregem will proceed with pre-clinical safety studies of the USAG-1 neutralizing antibody and preparation of an investigational formulation for manufacturing. Tregem will develop the USAG-1 antibody for the primary indication of patients with congenital edentulism, a condition for which there is no fundamental treatment option. Furthermore, animal studies have confirmed that USAG-1 neutralizing antibodies can generate third growth teeth after permanent teeth. We believe that this finding could contribute to the improvement of oral frailty in the elderly.

Kyoto iCAP, believing that Tregem's technology could provide a new means of dental treatment, has subscribed to 200 million yen of the total 450 million yen raised through a third-party allotment of new shares. In addition to Kyoto iCAP, Astellas Venture Management LLC, Gemseki Corporation, Future Venture Capital Corporation, Kyoshin Social Capital Corporation, and Kyoto City Startup Support Fund No. 2 also participated in this financing.

Overview of Tregem Biopharma, Inc.

Establishment	May 2020
Business	Oral Care and Tooth Regeneration therapeutics
Head Office Location	Sakyo-ku, Kyoto
President & CEO	Honoka Kisaya